Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.
Quick take
- The factor v leiden test is a genetic test that looks for a specific inherited variant in the F5 gene. It is used to help assess risk for venous blood clots such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
- A positive result is not a diagnosis of an active clot. It means your inherited clotting tendency is higher than average; many people with Factor V Leiden never develop an abnormal clot.
- Testing is not useful for everyone. Current expert guidance generally discourages broad screening and favors testing only when the result could change prevention, pregnancy, hormone, surgery, or anticoagulation decisions.
- No fasting is usually needed. Molecular testing is typically performed on blood or a buccal swab, depending on the lab and ordering pathway.
- Cost varies by route. Doctor-ordered testing may be billed to insurance; cash-pay online options should be compared by total cost, including required clinician or order-review fees.
Seek urgent care now if you have symptoms of a possible blood clot, such as one-sided leg swelling or pain, sudden shortness of breath, chest pain, coughing blood, fainting, or a rapid heartbeat. A Factor V Leiden result cannot rule in or rule out an emergency clot.
What Factor V Leiden is
Factor V Leiden is the name for a specific inherited change in the F5 gene, which provides instructions for coagulation factor V, a protein involved in normal blood clotting. The variant makes factor V harder for activated protein C to turn off. As a result, the clotting process can stay active longer than usual, increasing the tendency to form abnormal venous clots. The National Library of Medicine’s MedlinePlus Genetics describes Factor V Leiden thrombophilia as the most common inherited form of thrombophilia.
The most important clinical concern is venous thromboembolism, or VTE. VTE includes deep vein thrombosis, a clot usually forming in the deep veins of the leg, and pulmonary embolism, when part of a clot travels to the lungs. Factor V Leiden is much less about everyday bleeding or bruising and much more about the chance of venous clotting in the setting of other risk factors.
Factor V Leiden is also different from factor V deficiency. Factor V Leiden is usually a clotting-risk condition. Factor V deficiency is a rare bleeding disorder caused by too little or poorly functioning factor V. Confusing the two can lead to the wrong questions and the wrong test.
What the Factor V Leiden test measures
Most consumer and clinical Factor V Leiden tests are molecular genetic tests. They look for the known Factor V Leiden variant in the F5 gene. Major laboratories list this test under names such as “Factor V Leiden Mutation Analysis” or “Factor V Leiden DNA Test.” For example, Labcorp lists allele-specific PCR for its Factor V Leiden mutation analysis, while the Quest Diagnostics test directory lists polymerase chain reaction and detection.
| Test type | What it tells you | Common role | Important limitations |
|---|---|---|---|
| Molecular Factor V Leiden test | Whether the specific F5 Factor V Leiden variant is absent, present in one copy, or present in two copies | Confirmation and genotype classification | Does not diagnose an active clot and does not predict exactly who will clot |
| Activated protein C resistance assay | Whether the blood shows resistance to activated protein C | Functional screen sometimes followed by molecular confirmation | Can be affected by some clinical conditions and medications; abnormal results may need confirmation |
| Thrombophilia panel | May include Factor V Leiden plus prothrombin variant, protein C, protein S, antithrombin, antiphospholipid tests, and others | Selected evaluations after VTE, recurrent events, unusual-site clots, or pregnancy-related scenarios | Some panel components are timing-sensitive; broader panels can create confusing or low-value results if ordered without a plan |
A molecular Factor V Leiden test is usually a one-time test because inherited DNA generally does not change over a person’s lifetime. There are rare exceptions and laboratory caveats, such as specimen mix-ups, bone marrow transplantation, transfusion-related considerations, or unusual mosaicism, but repeat testing is not typically needed when the original clinical-grade result is clear and documented.
Who should consider a Factor V Leiden test?
The best reason to order a Factor V Leiden test is not curiosity alone; it is whether the result could change a real decision. The American Society of Hematology notes that thrombophilia testing can be costly and controversial, and its 2023 guidance favors testing only in specific clinical situations rather than broadly testing everyone.
Testing may be discussed with a clinician when there is a personal history of VTE, especially if the clot occurred at a young age, was recurrent, occurred in an unusual location, happened during pregnancy or the postpartum period, or was associated with estrogen-containing contraceptives or hormone therapy. Testing may also be considered in selected family situations, particularly if a close relative has a known high-risk thrombophilia and the result would influence pregnancy planning, postpartum prevention, surgery planning, or hormone choices.
The GeneReviews chapter on Factor V Leiden thrombophilia lists clinical situations in which the condition may be suspected, including VTE at a young age, family history of VTE, low activated protein C resistance assay values, VTE provoked by pregnancy, postpartum VTE, or VTE associated with combined oral contraceptive use. It also emphasizes that testing of relatives is not a simple yes-or-no issue and should be individualized.
When testing is often not recommended
Routine Factor V Leiden screening is often low value in people with no clot history and no clear management question. GeneReviews states that testing should not routinely be performed for several groups, including asymptomatic adult family members of individuals known to have a Factor V Leiden variant, routine testing in unaffected individuals before pregnancy or estrogen use, asymptomatic children, prenatal testing, and newborn testing.
The older CDC-linked EGAPP recommendation also cautioned against routine testing for Factor V Leiden and prothrombin variants in adults with idiopathic VTE when the goal is deciding on longer-term anticoagulation, and against testing asymptomatic adult family members solely to decide on preventive anticoagulant medication. That EGAPP summary is not the only guidance clinicians use today, but it captures an enduring point: a genetic risk result should not be ordered unless there is a reasonable path from result to action.
How to interpret Factor V Leiden results
A Factor V Leiden report usually falls into one of three categories. The exact wording varies by laboratory, so use the language and reference notes on your report.
| Possible result | Plain-language meaning | What it may imply |
|---|---|---|
| No Factor V Leiden variant detected | The tested variant was not found | Your clot risk may still be affected by surgery, pregnancy, cancer, immobility, estrogen use, obesity, smoking, age, antiphospholipid syndrome, or other inherited factors |
| Heterozygous / one copy detected | You inherited one copy of the Factor V Leiden variant | Venous clot risk is increased, but many carriers never have a clot; decisions depend heavily on personal and family history |
| Homozygous / two copies detected | You inherited two copies of the variant | Risk is higher than with one copy; clinician-guided planning is especially important for pregnancy, estrogen exposure, surgery, immobilization, and prior VTE |
Relative risk numbers can sound alarming, but absolute risk is more useful for everyday decisions. MedlinePlus Genetics reports that about 1 in 1,000 people in the general population develop an abnormal clot each year; having one copy of Factor V Leiden increases that risk to about 3 to 8 in 1,000, and having two copies may raise it as high as 80 in 1,000. MedlinePlus also notes that only about 10% of people with the Factor V Leiden mutation ever develop abnormal clots.
Risk is not determined by the gene alone. Other factors can raise clot risk, including increasing age, obesity, injury, surgery, smoking, pregnancy, cancer, prolonged travel or immobilization, central venous catheters, oral estrogen-containing contraceptives, and hormone replacement therapy. A Factor V Leiden result is best interpreted as one piece of a larger clot-risk profile.
Does a positive result mean blood thinners?
Not automatically. GeneReviews states that, in the absence of a thrombosis history, long-term preventive anticoagulation is not routinely recommended for asymptomatic heterozygous individuals. People who have had a clot are managed based on the type of clot, whether it was provoked, recurrence risk, bleeding risk, patient preferences, and current anticoagulation guidelines. A genetic result may inform the conversation, but it should not replace individualized medical decision-making.
Pregnancy, birth control, and hormone therapy
Factor V Leiden can matter in reproductive health because pregnancy, the postpartum period, and estrogen-containing medications can increase clot risk. MedlinePlus Genetics describes a slightly increased risk of pregnancy loss, while also noting that most women with Factor V Leiden thrombophilia have normal pregnancies. GeneReviews states that women with thrombophilia should have individualized pregnancy risk assessment and that antepartum prophylactic anticoagulation is not recommended solely to prevent a first VTE in heterozygous women, while prophylaxis is suggested for some homozygous or double-heterozygous situations.
If you are considering estrogen-containing birth control, hormone replacement therapy, fertility treatment, or pregnancy and you have a personal or family clot history, it is worth discussing Factor V Leiden testing and alternatives with an obstetrician-gynecologist, primary care clinician, hematologist, or genetic counselor.
Preparation and sample collection
For molecular Factor V Leiden testing, preparation is usually simple:
- Fasting: usually not required.
- Sample type: blood is common; some laboratories also accept buccal swab specimens.
- Timing: because DNA testing is generally stable, it is not usually tied to time of day or meals.
- Medications: do not stop anticoagulants, hormones, aspirin, or any prescribed medication just to test unless your clinician specifically tells you to. Molecular testing is different from functional clotting assays, some of which can be affected by anticoagulants or acute illness.
- Documents: bring the lab order, photo ID, insurance card if applicable, and any prior family member report if testing is being done for a known familial variant.
Lab-specific details vary. Labcorp lists whole blood or a Labcorp buccal swab kit as acceptable specimen types for its Factor V Leiden mutation analysis, with a typical turnaround time of 5 to 7 days. Quest lists whole blood in an EDTA tube as the preferred specimen and notes that no patient preparation is specified. Online ordering services may add time for clinician review, order release, lab processing, and result posting.
Cost and ordering options
There are three common ways people encounter a Factor V Leiden test: through a clinician and insurance, through a cash-pay online lab-ordering service, or as part of a broader genetic or thrombophilia evaluation. These routes can produce very different out-of-pocket costs.
Methodology for the examples below: the table compares publicly visible consumer cash pricing found on provider pages at the time of review, adds mandatory order-review or physician fees when shown, and notes collection network or restrictions when the provider states them. Prices can change, coupon codes may alter totals, and insurance billing is not comparable to cash-pay pricing because deductibles, payer contracts, and medical-necessity rules differ.
| Ordering route / provider example | Publicly listed test price | Mandatory added fee shown | Effective listed cost to the patient | Collection / availability notes |
|---|---|---|---|---|
| Walk-In Lab — Factor V Leiden Mutation Analysis Blood Test | $249.00 | $6.00 per-order physician fee | $255.00 before any optional discounts | Page lists Labcorp and Quest test codes and blood collection; stated result time 5–8 days; availability may vary by state and lab location |
| Marek Diagnostics — Factor V Leiden Mutation, DNA Analysis | $175.00 | No separate mandatory physician fee was visible on the product page reviewed | $175.00 before any checkout-specific charges | Page describes online purchase, healthcare-provider review, Quest collection, typical results within 14 business days, cash-pay model, and inability to process diagnostic lab orders for residents of New York, New Jersey, and Rhode Island |
| Clinician-ordered testing billed through insurance | Not a single public consumer price | May include office visit, phlebotomy, lab, facility, or deductible costs | Depends on medical necessity, payer policy, network status, deductible, and coinsurance | Often best when testing is part of a clot, pregnancy, anticoagulation, or family-risk evaluation |
Quest’s test directory lists CPT code 81241 and notes that the CPT code is subject to a Medicare Limited Coverage Policy and may require an advance beneficiary notice when ordering. Labcorp also lists CPT 81241 for its Factor V Leiden mutation analysis. If you plan to use insurance, ask the ordering office and insurer whether diagnosis codes, prior authorization, or coverage criteria apply. If you are paying cash, compare the total cost, not just the test sticker price.
Limitations to understand before ordering
A negative result does not mean “no clot risk.” Factor V Leiden is one inherited risk factor. People without the variant can still develop DVT or PE due to surgery, hospitalization, cancer, pregnancy, estrogen therapy, long travel, immobilization, trauma, age, obesity, smoking, antiphospholipid syndrome, or other inherited thrombophilias.
A positive result does not predict exactly what will happen. Labcorp’s test description states that the result cannot predict the occurrence or recurrence of a thrombotic event. This is why counseling and clinical context matter. A healthy 24-year-old heterozygous carrier with no family history does not have the same practical risk profile as a 45-year-old homozygous carrier with prior PE and upcoming major surgery.
It is mainly about venous clots. Factor V Leiden is most strongly associated with venous thromboembolism. It is not usually the primary explanation for arterial events such as heart attack or stroke. If arterial clotting, recurrent pregnancy loss, low platelets, or autoimmune symptoms are part of the story, clinicians may consider other evaluations, such as antiphospholipid syndrome testing, rather than relying on Factor V Leiden alone.
Broad panels can be a double-edged sword. A panel may be appropriate after certain VTE events or in specialist care, but broader is not always better. Some tests are affected by acute thrombosis, pregnancy, liver disease, inflammation, or anticoagulant therapy. Others may have limited clinical utility. ASH’s thrombophilia guidance and GeneReviews both emphasize using testing selectively and interpreting it within a management plan.
Practical next steps
- Write down the decision you are trying to make. Examples: “Can I use estrogen-containing birth control?” “Do I need a pregnancy prevention plan?” “Should my anticoagulation plan change after a clot?” “Should relatives be tested?”
- Collect family details if possible. A first-degree relative’s actual report is more useful than a vague memory of “a clotting gene.” Note whether relatives had DVT, PE, unusual-site clots, miscarriages, or clots after surgery, pregnancy, or hormones.
- Ask whether a targeted test or a broader evaluation is better. If a specific Factor V Leiden variant is known in the family, targeted testing may be enough. If you have had VTE, your clinician may consider a broader clotting history and selected tests.
- Compare total cost before checkout. Include required physician fees, collection fees, state restrictions, insurance deductible, and whether the result will be accepted by your treating clinician.
- Plan result follow-up before testing. A genetic result can affect pregnancy, contraception, hormone therapy, perioperative planning, and relatives. Have a clinician or genetic counselor available if the result may change medical decisions.
Educational note: This article is for general health education and is not a diagnosis or a personal testing recommendation. Decisions about thrombophilia testing, anticoagulation, pregnancy management, and hormone therapy should be made with a qualified healthcare professional who knows your history.
FAQs about the Factor V Leiden test
What does a Factor V Leiden test look for?
It looks for a specific inherited variant in the F5 gene that causes resistance to activated protein C. A molecular test can tell whether the variant is absent, present in one copy, or present in two copies.
Is Factor V Leiden the same as having a blood clot?
No. Factor V Leiden is an inherited risk factor. A DVT or PE is an active or prior clotting event. If you have symptoms of a possible clot, you need urgent clinical evaluation, not a genetic screening test.
Do I need to fast?
No fasting is usually required for molecular Factor V Leiden testing. Follow the instructions from the lab or ordering clinician, especially if other tests are being collected at the same time.
Can I take the test while on blood thinners?
Molecular DNA testing is generally not affected by anticoagulants in the same way functional clotting assays can be. However, never stop a blood thinner for testing unless your clinician tells you to. If a thrombophilia panel is being ordered, ask which components are timing-sensitive.
What does heterozygous Factor V Leiden mean?
Heterozygous means one copy of the variant was found. It increases venous clot risk, but many heterozygous people never develop a clot. The practical meaning depends on other risk factors, including prior VTE, family history, hormones, pregnancy, surgery, immobility, smoking, obesity, cancer, and age.
What does homozygous Factor V Leiden mean?
Homozygous means two copies of the variant were found. This is less common and generally carries a higher clotting risk than having one copy. A homozygous result deserves clinician-guided planning, especially around pregnancy, postpartum care, major surgery, long immobilization, and estrogen-containing medications.
Should my children be tested?
Routine testing of asymptomatic children is generally not recommended in many guidance discussions because the result often does not change childhood management and can create anxiety or privacy concerns. Exceptions may exist in families with severe thrombosis history or when a specialist believes the result will change care.
Should I test before using birth control?
Routine screening of everyone before estrogen-containing contraception is not generally recommended. Testing may be worth discussing if you have a personal clot history, a strong family history of VTE, or a known high-risk thrombophilia in a close relative. Non-estrogen options may be considered depending on your situation.
Can 23andMe or ancestry testing replace a clinical Factor V Leiden test?
Consumer genetic data may identify certain variants, but it should not replace a clinical-grade test when medical decisions are involved. If the result could affect anticoagulation, pregnancy, surgery, or hormone therapy, use a test ordered and reported through a clinical laboratory and review it with a qualified professional.
Is MTHFR part of Factor V Leiden testing?
No. Factor V Leiden involves the F5 gene. MTHFR variants are different and are not considered useful thrombophilia tests in many modern VTE evaluations. If a panel includes MTHFR, ask why it is being ordered and how the result would change management.
Sources
- MedlinePlus Genetics: Factor V Leiden thrombophilia
- GeneReviews: Factor V Leiden Thrombophilia
- American Society of Hematology: 2023 thrombophilia testing guideline statement
- CDC archive: EGAPP recommendation on Factor V Leiden and prothrombin testing
- Labcorp: Factor V Leiden Mutation Analysis
- Quest Diagnostics: Factor V Leiden Mutation Analysis
- Walk-In Lab: Factor V Leiden Mutation Analysis Blood Test
- Marek Diagnostics: Factor V Leiden Mutation, DNA Analysis
